Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light

Selectivity remains a major challenge in anticancer therapy, which potentially can be overcome by local activation of a cytotoxic drug. Such triggered activation can be obtained through modification of a drug with a photoremovable protecting group (PPG), and subsequent irradiation in the chosen place and time. Herein, the design, synthesis and biological evaluation is described of a photoactivatable MDM2 inhibitor, PPG-idasanutlin, which exerts no functional effect on cellular outgrowth, but allows for the selective, noninvasive activation of antitumor properties upon irradiation visible light, demonstrating activation with micrometer, single cell precision. The generality of this method has been demonstrated by growth inhibition of multiple cancer cell lines showing p53 stabilization and subsequent growth inhibition effects upon irradiation. Light activation to regulate protein–protein interactions between MDM2 and p53 offers exciting opportunities to control a multitude of biological processes and has the potential to circumvent common selectivity issues in antitumor drug development.

[1]  R. Gropeanu,et al.  Ethyl substituted coumarin-4-yl derivatives as photoremovable protecting groups for amino acids with improved stability for SPPS , 2012 .

[2]  Wiktor Szymanski,et al.  Wavelength-selective cleavage of photoprotecting groups: strategies and applications in dynamic systems. , 2015, Chemical Society reviews.

[3]  T. Poulsen,et al.  Ester coupling reactions--an enduring challenge in the chemical synthesis of bioactive natural products. , 2015, Natural product reports.

[4]  B. Kuhn,et al.  Practical Synthesis of MDM2 Antagonist RG7388. Part 2: Development of the Cu(I) Catalyzed [3 + 2] Asymmetric Cycloaddition Process for the Manufacture of Idasanutlin , 2016 .

[5]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[6]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[7]  S. Nonell,et al.  Development of Green/Red-Absorbing Chromophores Based on a Coumarin Scaffold That Are Useful as Caging Groups. , 2017, The Journal of organic chemistry.

[8]  J. Moslehi,et al.  Cardiovascular Toxic Effects of Targeted Cancer Therapies. , 2016, The New England journal of medicine.

[9]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[10]  Zizhong Li,et al.  Practical Synthesis of MDM2 Antagonist RG7388. Part 1: A Cu(II)-Catalyzed Asymmetric [3 + 2] Cycloaddition , 2016 .

[11]  Jean-Yves Blay,et al.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. , 2012, The Lancet. Oncology.

[12]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[13]  A. Massaguer,et al.  A Green Light-Triggerable RGD Peptide for Photocontrolled Targeted Drug Delivery: Synthesis and Photolysis Studies. , 2016, The Journal of organic chemistry.

[14]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[15]  R. Medema,et al.  Transient activation of p53 in G2 phase is sufficient to induce senescence. , 2014, Molecular cell.

[16]  David M. Thomas,et al.  Clinical Overview of MDM2/X-Targeted Therapies , 2016, Front. Oncol..

[17]  D. Trauner,et al.  A roadmap to success in photopharmacology. , 2015, Accounts of Chemical Research.

[18]  D. Chenoweth,et al.  Synthesis and properties of lysosome-specific photoactivatable probes for live-cell imaging , 2015, Chemical science.

[19]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[20]  H. Möller,et al.  Spatio-temporal control of cellular uptake achieved by photoswitchable cell-penetrating peptides. , 2016, Chemical communications.

[21]  S. Agarwal,et al.  The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma , 2015, Cell Death Discovery.

[22]  R. Givens,et al.  Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy , 2012, Chemical reviews.

[23]  B. Feringa,et al.  Orthogonal control of antibacterial activity with light. , 2014, ACS chemical biology.

[24]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[25]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[26]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[27]  Gooitzen M van Dam,et al.  Emerging Targets in Photopharmacology. , 2016, Angewandte Chemie.

[28]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[29]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[30]  N. Emptage,et al.  Wavelength-orthogonal photolysis of neurotransmitters in vitro. , 2012, Chemical communications.